Lucida Medical announced today that it received CE mark approval for its machine learning-based prostate cancer detection software.
Cambridge, UK-based Lucida’s Prostate Intelligence (Pi) software offers a way for radiologists to assess and report MRI imaging studies and support the decision of whether or not to perform a biopsy, while also accurately targeting biopsies where needed, according to a news release.
The company touts Pi as capable of offering rapid “one-stop-shop” diagnoses that enable patients to get an MRI, report and biopsy in one visit while ensuring consistent reporting quality across the imaging networks.
Lucida’s technology uses radiogenomics, machine learning and image processing to analyze the MRI scans. The company touted results presented at the March 2021 European Congress of Radiology indicating that Pi can help automate labor-intensive tasks like marking out lesions while avoiding unnecessary invasive biopsies.
“Today, about half of cancers are found when they have already spread and this makes them difficult and costly to treat,” Lucida CEO & co-founder Dr. Antony Rix said in the release. “Our unique approach could allow patients to get exactly the tests, diagnosis and treatment that they need. With around 20 million new cases of cancer diagnosed each year worldwide, there is enormous potential for us to improve patients’ outcomes and reduce costs for health systems like the NHS.”